Home Newsfeeds Telsey Advisory Group Reiterates Market Perform on Stitch Fix, Maintains $5 Price Target

Telsey Advisory Group Reiterates Market Perform on Stitch Fix, Maintains $5 Price Target

Telsey Advisory Group analyst Dana Telsey reiterates Stitch Fix (NASDAQ:SFIX) with a Market Perform and maintains $5 price target.

byBenzinga Newsdesk

March 8, 2023

1 minute read

Telsey Advisory Group analyst Dana Telsey reiterates Stitch Fix (NASDAQ:SFIX) with a Market Perform and maintains $5 price target.

Analyst Ratings

The Latest Analyst Ratings for Conmed

By Benzinga Insights

April 27, 12:00 PM

Conmed (NYSE:CNMD) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish…

CNMD

Novavax (NVAX) Down As EU Adds Side Effects To COVID Jab Label

By Zacks

July 15, 12:14 PM

Shares of Novavax (NASDAQ: NVAX) fell 26.2% on Jul 14, after the European Medicines Agency's (TSE: EMA) Pharmacovigilance Risk Assessment Committee ("PRAC") updated the product label of Nuvaxovid, the company's COVID-19 vaccine, to include some potential side effects like severe aller

BNTX

Equillium Announces Preclinical Data From New Orally Deliverable Multi-Cytokine Inhibitor In Presentation At The 18th Annual Peptide Therapeutics Symposium

By Benzinga Newsdesk

October 16, 8:16 AM

Equillium Inc. (NASDAQ:EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced a presentation at the 18th Annual Peptide

JP Morgan Maintains Overweight on Zoetis, Lowers Price Target to $225

By Benzinga Newsdesk

October 17, 8:49 AM

JP Morgan analyst Chris Schott maintains Zoetis (NYSE:ZTS) with a Overweight and lowers the price target from $250 to $225.

ZTS

Telsey Advisory Group Reiterates Market Perform on Stitch Fix, Maintains $5 Price Target

Related Posts

The Latest Analyst Ratings for Conmed

Novavax (NVAX) Down As EU Adds Side Effects To COVID Jab Label

Equillium Announces Preclinical Data From New Orally Deliverable Multi-Cytokine Inhibitor In Presentation At The 18th Annual Peptide Therapeutics Symposium

JP Morgan Maintains Overweight on Zoetis, Lowers Price Target to $225